CVD, the predominant cause of mortality in T2D, requires therapeutic strategies extending beyond glucose control
This article examines how each medicine works, what is currently known about their combined use, the potential risks involved, and why specialist medical guidance is essential before considering either agent
1a) involved in binding to the human GLP-1R (hGLP-1R) core and four of the six C-terminal residues (excepting Ala 25 to Thr and Val 33 to Leu) involved in binding to the hGLP-1R N-terminal domain are conserved in pGLP-1 26,27,28
GLP-1 is rapidly degraded by an enzyme named dipeptidyl peptidase-IV (DPP-4), converting to bioinactive products GLP-1 (9-36) and GLP-1 (9-37) ( GLP-1 exerts its function by binding to GLP-1R and is involved in the development and progression of many diseases ( GLP-1R agonists (GLP-1RAs) are a group of GLP-1 analogues that are resistant to DPP4-mediated degradation, working through activating GLP-1R and its downstream signaling ( The expression of GLP-1R remains controversial due to the lack of specific antibody against GLP-1R, with most of the literatures using qPCR to detect mRNA levels (26, 27)
Do not remove the outer or inner needle caps yet
